236 related articles for article (PubMed ID: 8602375)
1. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of quantitative liver function tests to clinical, laboratory chemical and biopsy findings in patients with liver diseases].
Albers I; Hartmann H; Creutzfeldt W
Z Gastroenterol; 1988 Feb; 26(2):130-6. PubMed ID: 2577930
[TBL] [Abstract][Full Text] [Related]
3. [Antipyrine clearance in liver resections].
Fiorentini MT; Fracchia M; Biondi AM; Capussotti L; De La Pierre M; Molino G
Minerva Dietol Gastroenterol; 1990; 36(4):209-13. PubMed ID: 2089284
[TBL] [Abstract][Full Text] [Related]
4. Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.
Sheng QS; Lang R; He Q; Yang YJ; Zhao DF; Chen DZ
Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):46-9. PubMed ID: 19208514
[TBL] [Abstract][Full Text] [Related]
5. Hepatic drug clearance in patients with mild cystic fibrosis.
Kearns GL; Crom WR; Karlson KH; Mallory GB; Evans WE
Clin Pharmacol Ther; 1996 May; 59(5):529-40. PubMed ID: 8646824
[TBL] [Abstract][Full Text] [Related]
6. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
7. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
8. Autonomic function in chronic liver disease assessed by Heart Rate Variability Study.
Coelho L; Saraiva S; Guimaräes H; Freitas D; Providência LA
Rev Port Cardiol; 2001 Jan; 20(1):25-36. PubMed ID: 11291332
[TBL] [Abstract][Full Text] [Related]
9. Caffeine clearance by two point analysis: a measure of liver function in chronic liver disease.
Wittayalertpanya S; Israsena S; Thamaree S; Tongnopnoua P; Komolmit P
Tokai J Exp Clin Med; 1996 Dec; 21(4-6):195-201. PubMed ID: 9300980
[TBL] [Abstract][Full Text] [Related]
10. Hepatic parenchymal cell volume and the indocyanine green tolerance test.
Hashimoto M; Watanabe G
J Surg Res; 2000 Aug; 92(2):222-7. PubMed ID: 10896825
[TBL] [Abstract][Full Text] [Related]
11. In vivo estimates of hepatic binding protein concentration: correlation with classical indicators of hepatic functional reserve.
Kudo M; Vera DR; Stadalnik RC; Trudeau WL; Ikekubo K; Todo A
Am J Gastroenterol; 1990 Sep; 85(9):1142-8. PubMed ID: 2389727
[TBL] [Abstract][Full Text] [Related]
12. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
[TBL] [Abstract][Full Text] [Related]
13. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
[TBL] [Abstract][Full Text] [Related]
14. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
von Mandach U; Jost G; Preisig R
Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
[TBL] [Abstract][Full Text] [Related]
15. Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
Birnie GG; Fitzsimons CP; Czarnecki D; Cooke A; Scobie G; Brodie MJ
Hepatogastroenterology; 1985 Aug; 32(4):163-7. PubMed ID: 2865199
[TBL] [Abstract][Full Text] [Related]
16. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
[TBL] [Abstract][Full Text] [Related]
17. Liver volume as a determinant of drug clearance in children and adolescents.
Murry DJ; Crom WR; Reddick WE; Bhargava R; Evans WE
Drug Metab Dispos; 1995 Oct; 23(10):1110-6. PubMed ID: 8654200
[TBL] [Abstract][Full Text] [Related]
18. Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects.
Andersen V; Sonne J; Larsen S
Scand J Gastroenterol; 1999 Aug; 34(8):813-7. PubMed ID: 10499483
[TBL] [Abstract][Full Text] [Related]
19. Plasma disappearance rate of indocyanine green in liver dysfunction.
Faybik P; Hetz H
Transplant Proc; 2006 Apr; 38(3):801-2. PubMed ID: 16647475
[TBL] [Abstract][Full Text] [Related]
20. [Serum concentration of bile acids and portal hypertension in cirrhotic patients. Possible correlations].
Tarantino G; Cambri S; Ferrara A; Marzano M; Liberti A; Vellone G; Ciccarelli AF
Riv Eur Sci Med Farmacol; 1989 Jun; 11(3):195-205. PubMed ID: 2640042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
